GenVec (Gaithersburg, Maryland) last month reported the launch of a Phase IIB randomized, placebo-controlled trial of its BioBypass angiogen for the treatment of severe coronary artery disease. The NOVA (NOGA Delivery of VEGF for Angina) trial will evaluate the effects of BioBypass on exercise tolerance, heart function, symptoms and quality of life in about 129 patients suffering from moderate to severe chest pain due to advanced coronary artery disease.